Related Experiment Video
Updated: Aug 14, 2026
Cholesterol Efflux Assay
Published on: March 6, 2012
Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II
S I Skarlatos1, N Duverger, D Rader
1Section of Experimental Atherosclerosis, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Insights
High-density lipoprotein (HDL) subfractions LpA-I and LpA-I:A-II show differential effects on cholesterol efflux from human macrophages. Their distinct roles in cardiovascular disease may not stem from macrophage cholesterol clearance.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Epidemiological studies suggest HDL subfraction LpA-I is more protective against cardiovascular disease than LpA-I:A-II.
- Previous research indicated LpA-I efficiently removes cholesterol from mouse adipocytes, while LpA-I:A-II is ineffective.
- LpA-I:A-II stimulates cholesterol efflux from rodent macrophages, but HDL's effect varies across macrophage types.
Purpose of the Study:
- To investigate if LpA-I:A-II can induce cholesterol efflux from cultured human monocyte-macrophages.
- To compare the effects of LpA-I:A-II and HDL3 on cholesterol efflux from human macrophages.
- To determine if differences in macrophage cholesterol efflux explain the differential anti-atherogenic effects of LpA-I and LpA-I:A-II.
Main Methods:
- Cultured human monocyte-macrophages were enriched with cholesterol via incubation with acetylated low-density lipoprotein (AcLDL).
- Cholesterol efflux was measured after incubation with LpA-I:A-II and HDL3.
- The impact of LpA-I:A-II on cholesterol accumulation in AcLDL-treated macrophages was assessed.
Main Results:
- Both LpA-I:A-II and HDL3 effectively stimulated cholesterol efflux from cholesterol-enriched human monocyte-macrophages.
- LpA-I:A-II reduced accumulated cholesterol by half when co-incubated with AcLDL in macrophages.
- These findings suggest macrophage cholesterol efflux is not the primary mechanism behind the differential anti-atherogenic effects of LpA-I and LpA-I:A-II.
Conclusions:
- The anti-atherogenic effects of HDL subfractions LpA-I and LpA-I:A-II do not appear to be mediated by their direct impact on human macrophage cholesterol efflux.
- Differential effects of these HDL subfractions on other biological processes may be responsible for their varying roles in cardiovascular disease development.
Abstract:
Previous epidemiological studies have suggested that the LpA-I subfraction of HDL is more protective than the LpA-I:A-II subfraction against the development of cardiovascular disease. A possible basis for a specific anti-atherogenic function of LpA-I emerged from studies of cholesterol efflux from cultured mouse adipocytes. LpA-I efficiently removed excess cholesterol from the mouse adipocytes, while LpA-I:A-II was ineffective. On the other hand, LpA-I:A-II was able to stimulate cholesterol efflux from a number of other cell types including rodent macrophages. Because of previously reported differences in HDL stimulation of cholesterol clearance from macrophages of different origins, we determined whether LpA-I:A-II could induce cholesterol efflux from cultured human monocyte-macrophages. Our findings showed that LpA-I:A-II and HDL3 effectively stimulated cholesterol efflux from human monocyte-macrophages enriched with cholesterol by incubation with AcLDL. LpA-I:A-II also decreased by one-half the amount of cholesterol accumulated when macrophages were incubated with AcLDL and LpA-I:A-II together. Thus, it would appear that the differential anti-atherogenic effects of LpA-I:A-II and LpA-I do not derive from their effects on macrophage cholesterol efflux. Possibly these HDL subfractions differentially affect other biologic processes that modulate the development of cardiovascular disease.
